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Abstract
Background:  Although primary lymphomas of the central nervous system (PCNSL) and
extracerebral diffuse large B-cell lymphoma (DLBCL) cannot be distinguished histologically, it is still
a matter of debate whether PCNSL differ from systemic DLBCL with respect to their molecular
features and pathogenesis. Analysis of the DNA methylation pattern might provide further data
distinguishing these entities at a molecular level.
Methods: Using an array-based technology we have assessed the DNA methylation status of 1,505
individual CpG loci in five PCNSL and compared the results to DNA methylation profiles of 49
DLBCL and ten hematopoietic controls.
Results: We identified 194 genes differentially methylated between PCNSL and normal controls.
Interestingly, Polycomb target genes and genes with promoters showing a high CpG content were
significantly enriched in the group of genes hypermethylated in PCNSL. However, PCNSL and
systemic DLBCL did not differ in their methylation pattern.
Conclusions: Based on the data presented here, PCNSL and DLBCL do not differ in their DNA
methylation pattern. Thus, DNA methylation analysis does not support a separation of PCNSL and
DLBCL into individual entities. However, PCNSL and DLBCL differ in their DNA methylation
pattern from non- malignant controls.
Background
Primary lymphomas of the central nervous system
(PCNSL) are highly malignant B-cell lymphomas con-
fined to the central nervous system (CNS) with a poor
prognosis [1]. They are considered as separate entity
within the updated WHO classification [1], although they
cannot be distinguished histologically and immunophe-
notypically from extracerebral diffuse large B-cell lym-
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phoma (DLBCL). However, based on the remarkably
worse clinical course and prognosis it is still a matter of
debate whether PCNSL differ from systemic DLBCL with
respect to their molecular features and pathogenesis.
Interphase cytogenetic and molecular genetic studies have
shown that PCNSL share a variety of features with sys-
temic DLBCL. These include rearranged immunoglobulin
(IG) gene segments with evidence for ongoing somatic
hypermutation, aberrant somatic hypermutation of non-
IG genes, translocations affecting the IG and BCL6 genes,
gains in chromosome band 18q21, and mutations of the
PRDM1 gene [2]. With respect to their gene expression
profile PCNSL segregate along the spectrum of systemic
DLBCL including the ABC- and GCB-types of DLBCL
[3,4].
Epigenetic silencing of functionally important genes by
DNA methylation may also contribute to PCNSL develop-
ment [5-10]. By studying DNA methylation of 14 tumor
suppressor genes in 25 PCNSL using methylation-specific
PCR, Chu et al. [5] demonstrated that all PCNSL had
methylated at least two of the genes studied. Although
these findings suggest DNA methylation of tumor sup-
pressor genes to be a common event in PCNSL, previous
studies on DNA methylation have been limited to a rather
small number of a few selected genes. The recent availabil-
ity of array-based techniques offers the opportunity for a
more comprehensive DNA methylation profiling [11,12].
Here, a series of PCNSL was studied for DNA methylation
of 1,505 CpG sites from 807 selected genes including a
significant number of genes relevant for tumorigenesis. By
comparing DNA methylation profiles of PCNSL to those
recently obtained for normal hematopoietic controls and
49 systemic DLBCL [12], we identified 194 genes to be dif-
ferentially methylated between PCNSL and normal con-
trols. Four genes were putatively differentially methylated
between PCNSL and systemic DLBCL. Based on the DNA
methylation pattern these lymphoma entities did not seg-
regate suggesting DNA methylation pattern of PCNSL and
systemic DLBCL to be highly comparable.
Methods
DNA extraction and samples
DNA samples from five tumors diagnosed as PCNSL (two
of ABC- and three of GCB-subtype, all from female
patients) as described recently [3] and classified according
to the WHO classification 2008 [1] were subjected to
array-based DNA methylation profiling. Systemic lym-
phoma manifestation was excluded by extensive staging.
All studies were approved by local ethics committees.
Informed consent was provided according to the Declara-
tion of Helsinki. DNA extraction was performed as
described previously [13]. The DNA samples of 49 sys-
temic DLBCL and of 10 normal controls have been
described in detail recently [12,14]. The tumor cell con-
tent of DLBCL samples was >70% as verified by a panel of
experienced pathologists.
DNA methylation profiling using universal BeadArrays
DNA methylation analyses were performed using the
GoldenGate Methylation Cancer Panel I (Illumina Inc.,
San Diego, CA) as described previously [12]. The array
allows assaying 1,505 CpG sites from 807 selected genes,
which include numerous genes relevant for tumorigenesis
including oncogenes, tumor suppressor genes, and genes
involved in metastasis, differentiation, cell cycle control,
and apoptosis. The complete dataset is provided as sup-
plementary information (Additional file 1). The repro-
ducibility and accuracy of the GoldenGate Cancer Panel I
based DNA methylation analysis has been demonstrated
extensively [11,12].
Analyses of the DNA methylation data obtained by the 
GoldenGate Methylation Cancer Panel I
DNA methylation profiling data from 10 hematopoietic
controls (analysed in replicates) and 49 systemic DLBCL
obtained recently with the same platform served for com-
parison and have been reanalyzed in this study [12]. As
detailed in Additional file 2, normal controls contained
two samples of tonsillar germinal center B-cells, two nor-
mal peripheral blood samples, and six lymphoblastoid
cell lines. Systemic DLBCL were classified as non molecu-
lar Burkitt lymphoma (non-mBL) by gene expression pro-
filing and included 29 ABC and 20 GCB-type DLBCL
[12,14]. Identification of imprinted CpGs and gender-spe-
cifically methylated CpGs on chromosome X has been
performed as described recently [12]. Using BeadStudio
software (ver.3, Illumina Inc., San Diego, CA) agglomera-
tive hierarchical clustering was performed in PCNSL, sys-
temic DLBCL, and normal hematopoietic controls
excluding CpG loci located in imprinted genes and X-
chromosomal genes with gender-specific methylation
(1,284 CpGs corresponding to 716 genes were included
for further analysis). The statistical analyses used to define
the different DNA methylation subgroups have been
detailed recently [12]. The data obtained from the arrays
were not normalized. In addition, differential methyla-
tion analysis (DMA) has also been performed using the
BeadStudio Software. CpG loci with calculated DiffScores
below -30 or above 30 (corresponding to a p-value of p >
0.001, based on a t-statistic) simultaneously showing an
absolute DeltaBeta value above 0.3 (corresponding to a
difference of 30% in the DNA methylation level) were
considered as differentially methylated. The global DNA
methylation data per case shows a bimodal distribution in
which beta values < 0.25 defines the unmethylated CpGs
and beta values> 0.75 the methylated CpGs [12]. Thus,
beta values below 0.25 and above 0.75 were selected as
threshold-values to define unmethylated and methylated
CpG loci for further analysis.BMC Cancer 2009, 9:455 http://www.biomedcentral.com/1471-2407/9/455
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Enrichment for PcG-marks and promoter classes in 
different DNA methylation groups
Identification of Polycomb target genes and promoter
classification into promoters with high (HCP), intermedi-
ate (ICP), and low (LCP) CpG content respectively, are
based on recent publications [15-17]. Annotation lists of
Polycomb group (PcG) marks and promoter classes were
compared with the genes analyzed for methylation via
gene symbol or locuslink ID. Proportions of genes in the
different methylation groups were compared with respect
to PcG-marks and promoter classes as described previ-
ously [12].
Principal component analysis (PCA)
PCA has been performed using the Omics Explorer, Ver-
sion 2.0 Beta (Qlucore AB, Lund, Sweden).
Gene ontology
The "Gene Annotation Tool to Help Explain Relation-
ships" (GATHER; http://gather.genome.duke.edu) has
been used to determine the enrichment of individual
ontology terms in the group of genes differentially meth-
ylated in PCNSL and normal controls (with respect to the
overall composition of the GoldenGate array). Ontology
terms with an at least twofold increase in numbers of
genes between the tested group and the array containing
at least five individual genes, were tested for significance
of enrichment by performing Fisher's exact test.
Statistics
Fisher's exact test and Mann-Whitney test were performed
using GraphPad Prism version 4.02 for Windows, Graph-
Pad Software, San Diego, CA.
Results
Array-based DNA methylation profiling of PCNSL
The BeadArray technology [11,18] was applied to perform
quantitative DNA methylation analyses of 1,505 individ-
ual CpGs corresponding to 807 genes relevant for tumor-
igenesis in five PCNSL. Results were compared to those
recently obtained for ten hematopoietic controls and 49
systemic DLBCL [12]. Genes known to be imprinted and
X-chromosomal genes with gender-specific methylation
were excluded from the analysis, as they are partially
methylated under physiological conditions and might
represent a confounding variable to classify cases accord-
ing to their DNA methylation profile. Thus, a total of
1,284 CpGs corresponding to 716 genes entered the anal-
ysis.
Identification of genes differentially methylated between 
PCNSL and hematopoietic controls
PCA based analysis applying most stringent conditions
differentiates normal controls from both PCNSL and sys-
temic DLBCL samples in a highly significant fashion (p =
1.2 × 10-12, q = 3.9157 × 10-11; Fig. 1A). 33 CpG loci (cor-
responding to 30 genes) differentiating between PCNSL
and controls performed in replicates were significantly
hypermethylated while three CpG loci showed
hypomethylation in PCNSL compared to hematopoietic
controls (Fig. 1B).
Supervised cluster analysis of the 1,284 CpGs comparing
the five PCNSL to ten hematopoietic controls resulted in
296 differentially methylated CpGs corresponding to 194
genes (Additional file 3). Of these 194 genes, 153 genes
were hypermethylated while 41 genes were hypomethyl-
ated in PCNSL. Unsupervised cluster analysis of the five
PCNSL and the 10 hematopoietic controls along with the
49 systemic DLBCL samples for all 1,284 CpGs separated
all lymphoma samples from normal controls (Fig. 1C).
These findings suggest that the methylation profile of
PCNSL strongly differs from that of normal hematopoi-
etic tissues including tonsillar germinal center B-cells and
lymphoblastoid cells.
CpG loci differentially methylated in PCNSL and systemic 
DLBCL
The methylation pattern of both PCNSL and systemic
DLBCL were very heterogeneous with respect to total DNA
methylation (data not shown). To address the question
whether the DNA methylation pattern of PCNSL differs
from that of systemic DLBCL, we compared DNA methyl-
ation values of 1,284 CpG loci from the five PCNSL with
those of the 49 systemic DLBCL. Of the 194 genes differ-
entially methylated between normal controls and PCNSL,
using the same analysis approach, 157 genes were among
the 174 genes differentially methylated between controls
and DLBCL (Additional file 4). Neither supervised nor
unsupervised cluster analysis separated PCNSL from sys-
temic DLBCL (Fig. 1C, D, and data not shown). A differ-
ential methylation analysis (DMA) of PCNSL and
systemic DLBCL cases yielded only four CpGs differen-
tially methylated between PCNSL and systemic DLBCL
(ESR1, EFNA1, MATK, and PDE1B). However, hierarchi-
cal cluster analysis performed on these four CpG loci
failed to distinguish PCNSL from systemic DLBCL (Addi-
tional file 5). Thus, methylation analysis of these CpG loci
does not allow a proper assignment of unknown samples
to either PCNSL or systemic DLBCL. Furthermore, PCA
failed to differentiate between PCNSL and systemic
DLBCL (Fig. 1A, and data not shown). In conclusion,
PCNSL did not exhibit a specific DNA methylation signa-
ture as compared to systemic DLBCL including more than
700 genes which had entered this study.
Classification of genes based on their DNA methylation 
pattern in PCNSL as compared to non-neoplastic 
hematopoietic tissues
To get further insight into DNA hypermethylation in
PCNSL, we compared the class of genes methylated in
PCNSL but not in controls (meP/umC, n = 138) to theBMC Cancer 2009, 9:455 http://www.biomedcentral.com/1471-2407/9/455
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classes of genes unmethylated or methylated in both
PCNSL and controls (umP/umC, n = 348 genes and meP/
meC, n = 91 genes), respectively. These groups provided
the basis for further analysis (Additional file 6).
The group of genes methylated in PCNSL but 
unmethylated in non-neoplastic hematopoietic controls is 
enriched for polycomb targets in embryonic stem cells and 
promoters with high CpG content
The group of genes unmethylated in the hematopoietic
controls but methylated in PCNSL was highly signifi-
cantly enriched for genes repressed by the polycomb
(PcG) repressing complexes (PRC2) in embryonic stem
cells compared to the genes present on the array (Fig. 2A;
RR = 2.55; p < 0.0001, Fisher's exact test). This group was
also enriched for the simultaneous presence of all three
PRC2 marks as described previously [12,15,16]: EED (RR
= 2.62), SUZ12 (RR = 2.68) and 3 mK27-H3 (RR = 2.54)
(Fig. 2B). However, the targets of a specific PRC2 mark
were not preferentially enriched in any group (Fig. 2C).
While the percentage of PcG target genes in the group of
genes unmethylated (um) in both controls (C) and
PCNSL (P) (umP/umC) did not differ significantly from
the one of the GoldenGate array (RR = 0.81; p = 0.1675),
the percentage of PcG target genes was significantly
reduced (RR = 0,30; p = 0.0010) in the group of genes
methylated (me) in both PCNSL and normal controls
(meP/meC) (Fig. 2A, B).
DNA methylation analyses in PCNSL as compared to hematopoietic controls and systemic DLBCL Figure 1
DNA methylation analyses in PCNSL as compared to hematopoietic controls and systemic DLBCL. (A) Princi-
pal Components Analysis (PCA) significantly separates control samples (blue circles) from PCNSL (orange circles) and systemic 
DLBCL (yellow circles) (p = 1.2 × 10-12; q = 3.9157 × 10-11) [40,41]. (B) Heatmap generated by applying the same conditions as 
in (A) red: high methylation level, green: low methylation level; blue squares: hematopoietic controls, orange squares: PCNSL; 
Hematopoieteic controls have been analysed in replicates and are shown as individual samples demonstrating good reproduci-
bility (C) Hierachical cluster analysis of DNA methylation data obtained from the 296 CpG loci (corresponding to 194 genes) 
differentially methylated between five PCNSL (orange) and 10 hematopoietic controls (blue) including 49 systemic DLBCL (yel-
low boxes). CpGs differentially methylated in PCNSL and normal controls did not distinguish between PCNSL and systemic 
DLBCL. (D) Unsupervised hierarchical cluster analysis of methylation values of all 1,284 CpGs from 10 hematopoietic controls 
(blue boxes), five PCNSL (orange boxes) and 49 systemic DLBCL (yellow boxes). While normal and malignant samples were 
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Since it was reported previously that particular promoters
with high CpG content and CpG islands become methyl-
ated in tumors [19-22], we have sorted the genes in the
groups defined above in genes having promoters with
high (HCP), intermediate (ICP), or low (LCP) CpG con-
tent [12], respectively. While the group of genes methyl-
ated in both PCNSL and controls (meP/meC) was
enriched for genes with low CpG content promoters (LCP;
RR = 2.21; p < 0.0001), the remaining two groups were
enriched by genes having promoters with high CpG con-
tent (umP/umC: RR = 1.17; p = 0.0023; meP/umC: RR =
1.35; p < 0.0001; Fig. 2D). The CpG loci belonging to
genes methylated in PCNSL and controls were further-
more significantly enriched for loci located outside of
CpG Islands (RR = 2.24; p < 0.0001).
The group of genes differentially methylated in PCNSL is 
enriched for genes involved in neurological processes and 
cellular signaling pathways
As genes studied with the methylation-specific BeadArray
were selected for their involvement in tumorigenesis, they
will "by definition" be deregulated in various tumors.
Even considering this bias, we tested whether genes differ-
entially methylated in PCNSL and normal controls were
Enrichment of PcG marks and HCP promotors in the group of genes methylated in PCNSL but unmethylated in non-neoplastic  hematopoietic tissues Figure 2
Enrichment of PcG marks and HCP promotors in the group of genes methylated in PCNSL but unmethylated 
in non-neoplastic hematopoietic tissues. Bar plot of the different DNA methylation subsets showing percentage and 
absolute numbers (numbers below each diagram) of (A) genes containing PcG marks in ESCs and (B) genes with one, two or 
three PcG marks, respectively. The meP/umC group was significantly enriched for PcG target genes (p < 0.0001; Fisher's exact 
test) and genes containing all three PcG marks (p < 0.0001). "array" reflects the distribution of the respective genes on the 
GoldenGate Cancer Panel I array. (C) Comparison of the content of EED, SUZ12 and 3 mK27-H3 target genes in the different 
groups and the GoldenGate array. The content of genes containing the individual marks is comparable in PCNSL. (D) Bar plot 
showing the percentage of promoter subtypes according to their CpG content in the different DNA methylation subsets. 
Genes de novo methylated in PCNSL (meP/umC) predominantly had promoters with high CpG content (p < 0.0001). In con-
trast, genes having promoters with low CpG content were enriched in the group showing high methylation in PCNSL and nor-
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enriched for specific Gene Ontology (GO) terms. Surpris-
ingly, we observed that terms particularly involved in neu-
rophysiological and perception processes were
significantly enriched (Additional file 7). However, the
same GO terms were also enriched in systemic DLBCL.
Thus, a PCNSL specific enrichment of individual GO
terms differing from DLBCL was not identified.
Discussion
In the present study, we determined DNA methylation
patterns in tumor samples of five patients suffering from
PCNSL and compared them to the methylation pattern of
49 systemic DLBCL and ten normal hematopoietic con-
trols, which have been characterized in detail before
[12,14]. The GoldenGate Cancer Panel I used in this study
offers the possibility to analyze 1,505 single CpG loci cor-
responding to 807 genes in parallel. To prevent any bias
because of gender specific DNA methylation and imprint-
ing effects, X-chromosomal genes and genes known to be
imprinted, the methylation extent of which varies under
normal physiological conditions, have been excluded
from further analyses. The reproducibility and the accu-
racy of this array based approach have been extensively
demonstrated before [12,18].
Of the 1,284 CpG loci focused on in this study, we identi-
fied 296 CpG loci to be differentially methylated between
normal hematopoietic controls and PCNSL correspond-
ing to 194 genes. These include numerous genes known to
affect tumorigenesis e.g. by influencing cell proliferation
(e.g. CCNA1), signal transduction (e.g. JAK3, IGF1, FGF3,
FGFR2, EGF, EGFR), differentiation (e.g. SOX1, SOX17,
SOX2, MYOD1, PAX6, HOXA9, HOXB13, ETS2) or spread
of tumor cells within the brain (e.g. MMP19,  MMP2,
MMP7) [23-26]. Furthermore, by applying a more strin-
gent PCA based approach, 36 CpG loci sufficient to differ-
entiate between PCNSL and hematopoietic controls in a
highly significant fashion have been identified.
Previous studies on DNA methylation in PCNSL were lim-
ited by their restriction to a low number of selected genes.
Our data are in line with Chu et al. and Gonzales-Gomez
et al. [5,8] analyzing the DNA methylation of CDKN2B,
DAPK1,  GSTP1,  MGMT,  MLH1,  RARB,  THBS1,  TIMP2,
and TIMP3 in PCNSL by MSP (Additional file 8) further
supporting the validity of our analysis. This is of special
interest, since our data on PCNSL are based on a minor
number of five cases, because of the limited availability of
sample material. Our results regarding CDKN2A  are
somewhat contradictory, however, one should keep in
mind that the CpG loci analyzed by the GoldenGate array
and by MSP are not identical. In addition, MSP data are
not quantitative [27] and analysis of the CDKN2A locus
might be affected by recurrent deletions of this gene in
PCNSL [28].
A further analysis of genes which were unmethylated in
hematopoietic controls and methylated in PCNSL (meP/
umC) showed a significant enrichment of genes which are
repressed by components of the PRC2 in embryonic stem
cells. Components of the PRC2 complex are essential for
the maintenance of the undifferentiated state of embry-
onic stem cells by suppressing genes called PcG target
genes, the activation of which leads to cellular differentia-
tion [16,29]. Indeed, hypermethylation of PcG target
genes has been described for several tumor entities [30]
including systemic mature aggressive B-cell lymphomas
[12]. This enrichment of genes controlled by PRC2 during
stem cell maintenance could lead to the hypothesis that
the tumor cells of PCNSL cells derive from a stem cell like
progenitor cell. Alternatively, dedifferentiation and epige-
netic reprogramming of an already differentiated precur-
sor cell could also explain the DNA methylation pattern
[12]. The latter model is supported by previous data lend-
ing support for the hypothesis that the tumor cells derived
from mature GC exit B-cells [3]. Finally, genes anyhow
silenced in the hematopoietic lineage could become
switched off by DNA methylation in tumor cells [12].
Interestingly, genes with three PcG-marks in the promoter
region were significantly enriched, while there was no
enrichment of a specific mark (neither EED, SUZ12 or 3
meK27-H3) in PCNSL. This is in line with results
obtained for systemic mature B-cell lymphomas [12]. Fur-
thermore, also similar to the scenario described for other
B-cell lymphomas, in particular genes with high CpG con-
tent promoters become methylated in PCNSL. This corre-
lates well with the known phenomenon that CpG islands
in promoter regions become methylated during tumori-
genesis [31-33].
In a recent study addressing genomic imbalances in
PCNSL [34] several genes hypermethylated in PCNSL,
including e.g. ERBB3, PDE1B, ASCL1, and BCAM  were
located in regions with recurrent genomic gains. However,
they were not expressed in the tumor [3]. Since DNA
methylation has been associated with gene repression in
numerous studies [35-37], our data on DNA methylation
might offer a putative explanation why increased gene
dosage does not lead to increased gene expression and
even transcriptional silencing in PCNSL. However, since a
number of recent studies have shown little correlation
between tumor specific hypermethylation and changes in
gene expression [12,38,39], this must be addressed by
future studies.
Conclusions
Comparing the DNA methylation state of 1,284 CpG loci
in PCNSL, systemic DLBCL, and hematopoietic controls,
a DNA methylation pattern exclusively specific for PCNSL
was not identified. The methylation data do not allow dis-BMC Cancer 2009, 9:455 http://www.biomedcentral.com/1471-2407/9/455
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tinguishing PCNSL from systemic DLBCL on the basis of
DNA methylation levels. However, the present study does
not exclude the possibility that analysis of a larger number
of CpG loci of the genome in a larger series of PCNSL
might identify PCNSL specific features.
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